A Spanish study led by scientists from the Cajal Institute and the National Center of Oncological Research (CNIO) combined the power of artificial neural networks and biological neuronal circuits to identify abnormal brain activity produced by secondary metastases in the CNS and classify these tumors. The work, published online on Aug. 30, 2023, in Cancer Cell, showed how damage in the brain did not depend on the tumor size but on the effect it produced on neuronal circuits, interrupting cell communication. Read More
Researchers from University of Michigan presented preclinical data for the novel oxylipin analogue CS-585 being developed as an antithrombotic agent. CS-585 was synthesized as an orally available analogue of 12(S)-hydroxy-eicosatrienoic (12-HETrE), with potent and selective prostacyclin (IP) receptor agonist activity and ability. Read More
Boston Immune Technologies and Therapeutics Inc. (BITT) has been awarded funding by the National Institutes of Health (NIH) to support the preclinical development of BITT-101, its CD40 antagonist antibody for treating Sjögren’s syndrome. The award will help support steps toward an IND filing next year. Read More
Longaevus Technologies Ltd. has announced the spin-off of Elastin Biosciences following breakthrough preclinical results of three of its assets. Elastin Biosciences has successfully conducted experiments and identified three novel drug combinations that inhibit elastin degradation and foster its deposition, leading to an increase in elastin expression by 5-fold, and improving aortic elasticity in aged mice in vivo. Read More
Aurigene Oncology Ltd. has reported the discovery of proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety via linker. They act as SMARCA2 and/or SMARCA4 degradation inducers and are reported to be useful for the treatment of cancer. Read More
Apolipoprotein C3 (APOC3) is one of the main regulators of triglyceride metabolism. Hypertriglyceridemia (HTG) is a major risk factor for cardiovascular disease and there is evidence that loss-of-function mutations in APOC3 correlate with decreased plasma triglyceride levels and subsequent reduced cardiometabolic dysfunction. Read More
Gilead Sciences Inc. and Novartis AG have jointly reported pyrazolopyridinone compounds potentially useful for the treatment of herpes virus infections. Read More
GTPase KRAS modulators have been described in a recent Quanta Therapeutics Inc. patent and are reported to be useful for the treatment of cancer. Read More
Interleukin-17A (IL-17A) is a pro-inflammatory cytokine involved in the pathogenesis of inflammatory, immune-mediated diseases such as psoriasis, psoriatic arthritis and others. Read More
Research at Pharos Ibio Co. Ltd. has led to the identification of son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer. Read More
A Pelemed Co. Ltd. patent details new indirubin derivatives acting as inhibitors of FLT3 (FLK2/STK1) and/or proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutants. They are reported to be useful for the treatment of acute myeloid leukemia. Read More
Synthesis and optimization of a series of 1H-pyrazolo[4,3d]pyrimidine molecules at Bristol Myers Squibb Co. led to the identification of compound [I] as the lead Toll-like receptor 7 (TLR7) agonist, with EC50 values of 21 and 94 nM for human and mouse TLR7, respectively. Read More
